Patents by Inventor Katherine A. Donovan

Katherine A. Donovan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION
    Publication number: 20240083847
    Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 14, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Tinghu Zhang, Tyler Faust, Katherine Donovan, Quan Cai, Zhengnian Li
  • Sulfonamide derivatives for protein degradation
    Patent number: 11807606
    Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 7, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Tinghu Zhang, Tyler Faust, Katherine Donovan, Quan Cai, Zhengnian Li
  • LIGANDS TO CEREBLON (CRBN)
    Publication number: 20230312575
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Application
    Filed: November 11, 2022
    Publication date: October 5, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • Small molecule degraders of polybromo-1 (PBRM1)
    Patent number: 11771697
    Abstract: The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 3, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric Fischer, Nathanael Gray, Radoslaw Nowak, Katherine Donovan, Tinghu Zhang, Yao Liu
  • SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20230011665
    Abstract: The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacety lase 6 (HDAC6) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: January 12, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220401564
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase (HCADC) (e.g., HDAC3) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 22, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • Ligands to cereblon (CRBN)
    Patent number: 11530219
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: December 20, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220387604
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylases 6 and 8 (HDAC6/8) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 8, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE
    Publication number: 20220226481
    Abstract: Disclosed are bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 21, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Nathanael Gray, Inchul You, Tinghu Zhang, Eric Fischer, Katherine Donovan, Emily Erickson, Alex Toker
  • DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1)
    Publication number: 20220177466
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by Kelch-like ECH-associated protein 1 (KEAP1). In some aspects, the present invention is directed to methods of treating diseases or disorders involving dysfunctional (e.g., dysregulated) KEAP1 activity, that entails administration of a therapeutically effective amount of a bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: June 9, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Guangyan Du, Nathaniel Henning, Jie Jiang, Eric Fischer, Katherine Donovan
  • CDK2/5 DEGRADERS AND USES THEREOF
    Publication number: 20220153722
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.
    Type: Application
    Filed: April 2, 2020
    Publication date: May 19, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Nicholas Kwiatkowski, Eric Fischer, Katherine Donovan, Tinghu Zhang, Mingxing Teng, Jie Jiang
  • DEGRADERS OF WEE1 KINASE
    Publication number: 20220047709
    Abstract: Disclosed are bifunctional compounds (degraders) that target Wee1 tyrosine kinase for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, David Scott, Zhengnian Li, Benika J. Pinch, Calla Olson, Eric S. Fischer, Radoslaw P. Nowak, Katherine A. Donovan
  • BISPECIFIC DEGRADERS
    Publication number: 20210300941
    Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 30, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • LIGANDS TO CEREBLON (CRBN)
    Publication number: 20210292325
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 23, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • IMMUNOMODULATORY COMPOUNDS
    Publication number: 20210284624
    Abstract: Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 16, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan, Hu Liu
  • DEGRADERS THAT TARGET PROTEINS VIA KEAP1
    Publication number: 20210276996
    Abstract: Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degradation by KEAP1 and the Cul3-based E3-ubiquitin ligase complex.
    Type: Application
    Filed: July 18, 2019
    Publication date: September 9, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Eric Fischer, Guangyan Du, Nozhat Safaee, Nathaniel Henning, Katherine Donovan
  • NEW CRBN MODULATORS
    Publication number: 20210277018
    Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 9, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1)
    Publication number: 20210038599
    Abstract: The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
    Type: Application
    Filed: April 30, 2019
    Publication date: February 11, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric Fischer, Nathanael Gray, Radoslaw Nowak, Katherine Donovan, Tinghu Zhang, Yao Liu
  • SMALL MOLECULE DEGRADERS THAT RECRUIT DCAF15
    Publication number: 20210002295
    Abstract: Disclosed herein are protein-targeting chimeric molecules (PROTACs) that recruit a specific ubiquitin ligase, such as LRL4DCAF15, to a chosen target protein, causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 7, 2021
    Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Quan Cai, Tinghu Zhang, Tyler Faust, Katherine Donovan
  • METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACS
    Publication number: 20200348285
    Abstract: Presented are methods of assessing the teratogenicity of agents by measuring the degradation of SALL4, and related compounds with reduced teratogenicity. Provided herein is a method for assessing the teratogenicity of an agent comprising: contacting an agent with SALL4; and measuring levels of SALL4, wherein the agent is teratogenic if SALL4 levels are substantially reduced in the presence of the agent relative to in the absence of the agent.
    Type: Application
    Filed: November 9, 2018
    Publication date: November 5, 2020
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Katherine Donovan